Payment overview · 2025
General Payments
$726.86
38 reported records · 15 companies
Healthcare provider profile · identity verified
Frampton W Henderson, MD
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBIA, SC · NPI 1407802184
Verified facts
What the public records show
CMS Open Payments records show Frampton W Henderson, MD received $726.86 in general payments during 2025 across 38 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $104.27 | 14.3% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $87.97 | 12.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.30 | 11.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.84 | 9.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $71.70 | 9.9% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $58.99 | 8.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.66 | 7.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.69 | 5.5% | 2 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $31.87 | 4.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.82 | 3.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $26.37 | 3.6% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $21.40 | 2.9% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $16.64 | 2.3% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $16.51 | 2.3% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $14.83 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $726.86 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $89.07 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $87.97 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $87.97 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $71.84 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $71.84 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $71.84 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.51 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $58.99 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.64 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.62 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.69 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $37.97 | 2 | 2025 |
Source payment records
|
|||||
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $31.87 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.75 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.75 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 14 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 120 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 31 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
120 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
31 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 568 | 155 |
| Atorvastatin Calcium | Atorvastatin Calcium | 460 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 360 | 111 |
| Alprazolam | Alprazolam | 320 | 45 |
| Losartan Potassium | Losartan Potassium | 283 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 259 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 68 |
| Pravastatin Sodium | Pravastatin Sodium | 198 | 55 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 165 | 28 |
| Trazodone Hcl | Trazodone Hcl | 165 | 45 |
| Montelukast Sodium | Montelukast Sodium | 164 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 50 |
| Tramadol Hcl | Tramadol Hcl | 153 | 36 |
| Metformin Hcl | Metformin Hcl | 148 | 47 |
| Lisinopril | Lisinopril | 123 | 40 |
| Omeprazole | Omeprazole | 123 | 40 |
| Carvedilol | Carvedilol | 122 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 122 | 22 |
| Farxiga | Dapagliflozin Propanediol | 120 | 28 |
| Lorazepam | Lorazepam | 116 | 25 |
| Potassium Chloride | Potassium Chloride | 115 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 34 |
| Clonazepam | Clonazepam | 107 | 16 |
| Ezetimibe | Ezetimibe | 101 | 30 |
| Metformin Hcl Er | Metformin Hcl | 100 | 28 |
| Gabapentin | Gabapentin | 99 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 42 |
| Eliquis | Apixaban | 90 | 22 |
| Jardiance | Empagliflozin | 90 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 35 |
| Allopurinol | Allopurinol | 84 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 26 |
| Glipizide Er | Glipizide | 84 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | 21 |
| Finasteride | Finasteride | 75 | 23 |
| Valsartan | Valsartan | 74 | 21 |
| Simvastatin | Simvastatin | 73 | 21 |
| Famotidine | Famotidine | 72 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | 11 |
| Verapamil Er | Verapamil Hcl | 70 | 19 |
| Pregabalin | Pregabalin | 69 | 14 |
| Ozempic | Semaglutide | 67 | 17 |
| Prednisone | Prednisone | 67 | 48 |
| Furosemide | Furosemide | 66 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 16 |
| Telmisartan | Telmisartan | 64 | 18 |
| Meloxicam | Meloxicam | 62 | 24 |
| Temazepam | Temazepam | 60 | suppressed |
| Baclofen | Baclofen | 59 | 27 |
| Diazepam | Diazepam | 59 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 19 |
| Sertraline Hcl | Sertraline Hcl | 53 | 17 |
| Atenolol | Atenolol | 52 | suppressed |
| Azithromycin | Azithromycin | 50 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 12 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 46 | 45 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Irbesartan | Irbesartan | 43 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 14 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 41 | suppressed |
| Mirtazapine | Mirtazapine | 41 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 14 |
| Rybelsus | Semaglutide | 40 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Eszopiclone | Eszopiclone | 37 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 37 | suppressed |
| Glipizide | Glipizide | 36 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 30 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Testosterone | Testosterone | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 29 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 20 |
| Chlorthalidone | Chlorthalidone | 30 | 12 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | 11 |
| Meclizine Hcl | Meclizine Hcl | 29 | 12 |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 15 |
| Ramipril | Ramipril | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Nystatin | Nystatin | 20 | 14 |
| Estradiol | Estradiol | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Neupro | Rotigotine | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $726.86 · 38 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, Barostim Neo System, CLOTTRIEVER BOLD CATHETER, COMIRNATY, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, INNOVAMATRIX AC, JARDIANCE, Leqembi, MOUNJARO, NEXPLANON, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error